Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.

MLA

Chaparro, María, et al. “Short and Long-Term Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: Results from the ENEIDA Registry.” Alimentary Pharmacology & Therapeutics, vol. 48, no. 8, Oct. 2018, pp. 839–51. EBSCOhost, https://doi.org/10.1111/apt.14930.

APA

Chaparro, M., Garre, A., Ricart, E., Iborra, M., Mesonero, F., Vera, I., Riestra, S., García-Sánchez, V., Luisa De Castro, M., Martin-Cardona, A., Aldeguer, X., Mínguez, M., de-Acosta, M. B., Rivero, M., Muñoz, F., Andreu, M., Bargalló, A., González-Muñoza, C., Pérez Calle, J. L., … Gisbert, J. P. (2018). Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Alimentary Pharmacology & Therapeutics, 48(8), 839–851. https://doi.org/10.1111/apt.14930

Chicago

Chaparro, María, Ana Garre, Elena Ricart, Marisa Iborra, Francisco Mesonero, Isabel Vera, Sabino Riestra, et al. 2018. “Short and Long-Term Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: Results from the ENEIDA Registry.” Alimentary Pharmacology & Therapeutics 48 (8): 839–51. doi:10.1111/apt.14930.